A network medicine approach to build a comprehensive atlas for the prognosisof human cancer

Briefings in Bioinformatics

Volumn 17, Issue 6, 2016, Pages 1044-1059

  Zhang, Fan ^a   Ren, Chunyan ^a   Lau, Kwun Kit ^a   Zheng, Zihan ^b   Lu, Geming ^a   Yi, Zhengzi ^a   Zhao, Yongzhong ^a   Su, Fei ^c   Zhang, Shaojun ^c   Zhang, Bin ^a   Sobie, Eric A ^a   Zhang, Weijia ^a   Walsh, Martin J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

landmark for cancer prognosis; Multi dimensional cancer genomic data; Networkmedicine; Systemmedicine

Indexed keywords

COPY NUMBER VARIATION; DNA METHYLATION; GENOMICS; HUMAN; NEOPLASM; PROGNOSIS;

DNA COPY NUMBER VARIATIONS; DNA METHYLATION; GENOMICS; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 84990061356     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbw076     Document Type: Article

References (68)

1. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
2. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
3. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
4. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
5. Liu Z, Zhang S. Toward a systematic understanding of cancers: a survey of the pan-cancer study. Front Genet 2014;5:194.
6. Yuan Y, Van Allen EM, Omberg L, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol 2014;32:644-52.
7. Xu C, Liu Y, Wang P, et al. Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival. Mol Cancer 2010;9:143.
8. Masica DL, Karchin R. Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res 2011;71:4550-61.
9. Kim S, Park T, Kon M. Cancer survival classification using integrated data sets and intermediate information. Artif Intell Med 2014;62:23-31.
10. Kim H, Huang W, Jiang X, et al. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci USA 2010;107:2183-8.
11. Zhao Q, Shi X, Xie Y, et al. Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA. Brief Bioinform 2015;16:291-303.
12. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
13. Zhang W, Liu Y, Sun N, et al. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer. Cell Rep 2013;4:542-53.
14. Das J, Gayvert KM, Bunea F, et al. ENCAPP: elastic-net-based prognosis prediction and biomarker discovery for human cancers. BMC Genomics 2015;16:263.
15. Varn FS, Ung MH, Lou SK, et al. Integrative analysis of survival-associated gene sets in breast cancer. BMC Med Genomics 2015;8:11.
16. Joung JG, Kim D, Lee SY, et al. Integrated analysis of microRNA-target interactions with clinical outcomes for cancers. BMC Med Genomics 2014;7(Suppl 1):S10.
17. Crijns AP, Fehrmann RS, de Jong S, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 2009;6:e24.
18. Patel VN, Gokulrangan G, Chowdhury SA, et al. Network signatures of survival in glioblastoma multiforme. PLoS Comput Biol 2013;9:e1003237.
19. Peri S, Navarro JD, Amanchy R, et al. Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res 2003;13:2363-71.
20. Betel D, Wilson M, Gabow A, et al. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008;36:D149-53.
21. Vergoulis T, Vlachos IS, Alexiou P, et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res 2012;40:D222-9.
22. Leiserson MD, Vandin F, Wu HT, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature Genetics 2015;47:106-14.
23. Vandin F, Clay P, Upfal E, et al. Discovery of mutated subnetworks associated with clinical data in cancer. Pac Symp Biocomput 2012;55-66.
24. Tibshirani RJ. Regression shrinkage and selection via the lasso. J Roy Stat Soc B 1996;58:267-88.
25. Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 2013;14:128.
26. Dienstmann R, Jang IS, Bot B, et al. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov 2015;5:118-23.
27. Dietlein F, Reinhardt HC. Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy. Clin Cancer Res 2014;20:5882-7.
28. Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10:143-53.
29. Appelqvist H, Waster P, Kagedal K, et al. The lysosome: from waste bag to potential therapeutic target. J Mol Cell Biol 2013;5:214-26.
30. Stehn JR, Haass NK, Bonello T, et al. A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res 2013;73:5169-82.
31. Groth-Pedersen L, Aits S, Corcelle-Termeau E, et al. Identification of cytoskeleton-associated proteins essential for lysosomal stability and survival of human cancer cells. PLoS One 2012;7:e45381.
32. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91.
33. Karanika S, Karantanos T, Li L, et al. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 2015;34:2815-22.
34. Schroer TA. Dynactin. Annu Rev Cell Dev Biol 2004;20:759-79.
35. Green RA, Wollman R, Kaplan KB. APC and EB1 function together in mitosis to regulate spindle dynamics and chromosome alignment. Mol Biol Cell 2005;16:4609-22.
36. Berrueta L, Tirnauer JS, Schuyler SC, et al. The APC-associated protein EB1 associates with components of the dynactin complex and cytoplasmic dynein intermediate chain. Curr Biol 1999;9:425-8.
37. Askham JM, Vaughan KT, Goodson HV, et al. Evidence that an interaction between EB1 and p150(Glued) is required for the formation and maintenance of a radial microtubule array anchored at the centrosome. Mol Biol Cell 2002;13:3627-45.
38. Nakamura M, Zhou XZ, Lu KP. Critical role for the EB1 and APC interaction in the regulation of microtubule polymerization. Curr Biol 2001;11:1062-7.
39. Wang YH, Zhou XB, Zhu HX, et al. Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway. Oncogene 2005;24:6637-45.
40. Liu M, Yang SB, Wang YH, et al. EB1 acts as an oncogene via activating beta-Catenin/TCF pathway to promote cellular growth and inhibit apoptosis. Mol Carcinog 2009;48:212-19.
41. Hitosugi T, Zhou L, Elf S, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 2012;22:585-600.
42. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82.
43. Wu L, Hui H, Wang LJ, et al. MicroRNA-326 functions as a tumor suppressor in colorectal cancer by targeting the nin one binding protein. Oncol Rep 2015;33:2309-18.
44. Li Y, Gao Y, Xu Y, et al. Down-regulation of miR-326 is associated with poor prognosis and promotes growth and metastasis by targeting FSCN1 in gastric cancer. Growth Factors 2015;33:267-74.
45. Liang ZX, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010;79:817-24.
46. Liu Z, Chen X, Wang Y, et al. PDK4 protein promotes tumorigenesis through activation of cAMP-response element- binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade. J Biol Chem 2014;289:29739-49.
47. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria- Kp channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51.
48. Sugden MC, Holness MJ. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 2003;284:E855-62.
49. Cheeseman IM, Desai A. Molecular architecture of the kinetochore-microtubule interface. Nat Rev Mol Cell Biol 2008;9:33-46.
50. Chan GKT, Jablonski SA, Starr DA, et al. Human Zw10 and ROD ave mitotic checkpoint proteins that bind to kinetochores. Nat Cell Biol 2000;2:944-7.
51. Obuse C, Iwasaki O, Kiyomitsu T, et al. A conserved Mis12 centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1. Nat Cell Biol 2004;6:1135. U1137.
52. Williams BC, Li ZX, Liu ST, et al. Zwilch, a new component of the ZW10/ROD complex required for kinetochore functions. Mol Biol Cell 2003;14:1379-91.
53. Kasuboski JM, Bader JR, Vaughan PS, et al. Zwint-1 is a novel Aurora B substrate required for the assembly of a dyneinbinding platform on kinetochores. Mol Biol Cell 2011;22:3318-30.
54. Caldas GV, DeLuca KF, DeLuca JG. KNL1 facilitates phosphorylation of outer kinetochore proteins by promoting Aurora B kinase activity. J Cell Biol 2013;203:957-69.
55. Kops GJ,Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-85.
56. Tibshirani RJ, Efron B. Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol 2002;1: Article1.
57. Patch AM, Christie EL, Etemadmoghadam D, et al. Corrigendum: whole-genome characterization of chemoresistant ovarian cancer. Nature 2015;527:398.
58. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
59. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
60. Kondo Y, Kanzawa T, Sawaya R, et al. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-34.
61. Maniatis T, Reed R. The role of small nuclear ribonucleoprotein particles in pre-mRNA splicing. Nature 1987;325:673-8.
62. Ligr M, Patwa RR, Daniels G, et al. Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer. Plos One 2011;6:e26250.
63. Miller G, Panov KI, Friedrich JK, et al. hRRN3 is essential in the SL1-mediated recruitment of RNA polymerase I to rRNA gene promoters. Embo J 2001;20:1373-82.
64. Yamamoto K, Yamamoto M, Hanada K, et al. Multiple protein-protein interactions by RNA polymerase I-associated factor PAF49 and role of PAF49 in rRNA transcription. Mol Cell Biol 2004;24:6338-49.
65. Vangsted AJ, Klausen TW, Gimsing P, et al. The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP. Ann Hematol 2011;90:675-84.
66. Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
67. Meng RD, Shelton CC, Li YM, et al. gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 2009;69:573-82.
68. Zou H, Hastie T. Regularization and variable selection via the elastic net. J Roy Stat Soc B 2005;67:301-20.